BZ Basel: Clinical cancer research under pressure

The current BZ Basel article "Medical progress in danger?" shows that clinical research in Switzerland is coming under increasing pressure. Interviewees such as Katharina Gasser and Pietro Gervasoni point to regulatory hurdles, lengthy approval processes and structural challenges for Switzerland as a research location.

Clinical cancer research is also affected by this. Although many studies are in the pipeline, their implementation is becoming increasingly difficult, especially for independent clinical research. As Swiss Cancer Institute, we are specifically committed to independent, patient-oriented cancer research. The systematic involvement of patients in our studies is a central component of our work.

Clinical trials are crucial for innovation, quality and access to new therapies. This makes it all the more important to shape the framework conditions in such a way that independent cancer research remains possible in Switzerland.